奈米眼藥開發-於角膜血管新生病變治療研究

Medicine and Dentistry

1. Agents Acting on the Eye 100%
2. Corneal Neovascularization 100%
3. Nanomedicine 100%
4. Nanoparticle 83%
5. Bioavailability 50%
6. Antiangiogenic Activity 50%
7. Epigallocatechin Gallate 50%
8. Therapeutic Agent 50%
9. Intraocular Drug Administration 33%
10. Gelatin 33%
11. Endothelial Cell 33%
12. Endothelium Cell 33%
13. Eye Disease 33%
14. Integrin 33%
15. Low Drug Dose 16%
16. Biological Activity 16%
17. Restylane 16%
18. Retinal Detachment 16%
19. Monoclonal Antibody Therapy 16%
20. Copolymer 16%
21. Ophthalmology 16%
22. Visual Acuity 16%
23. Aspartic Acid 16%
24. In Vitro 16%
25. Public Health 16%
26. Vasculotropin 16%
27. Vascular Endothelium 16%
28. Graft Failure 16%
29. Drug Bioavailability 16%
30. Angiogenesis 16%
31. Blood Flow 16%
32. Vision 16%
33. Cataract 16%

Pharmacology, Toxicology and Pharmaceutical Science

1. Agents Acting on the Eye 100%
2. Nanomedicine 100%
3. Cornea Neovascularization 100%
4. Nanoparticle 83%
5. Bioavailability 66%
6. Epigallocatechin Gallate 50%
7. Eye Disease 33%
8. Integrin 33%
9. Gelatin 33%
10. Inflammation 33%
11. Rabbit Model 16%
12. Aspartic Acid 16%
13. Copolymer 16%
14. Neovascularization (Pathology) 16%
15. Graft Failure 16%
16. Retina Detachment 16%
17. Drug Concentration 16%
18. Monoclonal Antibody 16%
19. Vasculotropin 16%
20. Hyaluronic Acid 16%
21. Cataract 16%